Erratum: Blocking p55PIK signaling inhibits proliferation and induces differentiation of leukemia cells (Cell Death and Differentiation (2012) 19 (1870-1879) DOI: 10.1038/cdd.2012.70);Blocking p55PIK signaling inhibits proliferation and induces differentiation of leukemia cells

Cell Death and Differentiation

Volumn 19, Issue 11, 2012, Pages 1870-1879

  Wang, G ^a   Deng, Y ^a   Cao, X ^a   Lai, S ^a   Tong, Y ^a   Luo, X ^a   Feng, Y ^a   Xia, X ^a   Gong, J ^a   Hu, J ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

leukemia; p55PIK; PI3K

Indexed keywords

MESSENGER RNA; P55PIK PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RNA ISOLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALIA;

EID: 84870991702     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.107     Document Type: Erratum

References (27)

1. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998; 67: 481-507.
2. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-254.
3. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 561-573.
4. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003; 3: 426-434.
5. Xia X, Cheng A, Akinmade D, Hamburger AW. The N-terminal 24 amino acids of the p55 gamma regulatory subunit of phosphoinositide 3-kinase binds Rb and induces cell cycle arrest. Mol Cell Biol 2003; 23:1717-1725.
6. Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, et al. Integrative genomic analysis of Phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 2007; 13: 5314-5321.
7. Hu J, Xia X, Cheng A, Wang G, Luo X, Reed MF, et al. A peptide inhibitor derived from p55PIK PI3K regulatory subunit is a novel cancer therapy. Mol Cancer Ther 2008; 7: 3719-3728.
8. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285:1569-1572.
9. Dietz GP, Bahr M. Synthesis of cell-penetrating peptides and their application in neurobiology. Methods Mol Biol 2007; 399:181-198.
10. Hotchkiss RS, McConnell KW, Bullok K, Davis CG, Chang KC, Schwulst SJ, et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. JImmunol 2006; 176: 5471-5477.
11. Luo P, Wang A, Payne KJ, Peng H, Wang JG, Parrish YK, et al. Intrinsic retinoic acid receptoralpha-cyclin-dependent kinase-activating kinase signaling involves coordination of the restricted proliferation and granulocytic differentiation of human hematopoietic stem cells. Stem Cells 2007; 25: 2628-2637.
12. Nishioka C, Ikezoe T, Yang J, Gery S, Koeffler HP, Yokoyama A. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 2009; 125: 1710-1720.
13. Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG, et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood 2004; 104: 3731-3738.
14. Altucci L, Leibowitz MD, Ogilvie KM, De Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007; 6: 793-810.
15. Alitalo R. Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts. Leuk Res 1990; 14: 501-514.
16. Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Res 2002; 62: 386-390.
17. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350.
18. Sachs L. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci USA 1996; 93: 4742-4749.
19. Lotem J, Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Seminars Cancer Biol 2002;12: 339-346.
20. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonalresistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-125.
21. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357: 258-265.
22. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol. 2003; 3: 338-343.
23. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
24. Matkovic K, Brugnoli F, Bertagnolo V, Banfic H, Visnjic D. The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells. Leukemia 2006; 20: 941-951.
25. Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol. 2010; 347: 79-104.
26. Cheng A, Wang S, Cai J, Rao MS, Mattson MP. Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Dev Biol 2003; 258: 319-333.
27. Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 2004; 104: 4219-4225.